.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
Researchers have identified new antiparasitic agents derived from 1,2,3-triazine, showing promising results against Trypanosoma cruzi and Leishmania mexicana. These neglected tropical diseases continue to pose significant public health challenges globally. Consequently, the discovery of novel chemical scaffolds is essential for improving therapeutic outcomes.
The study synthesized several derivatives, including 4-carboxylate-1,2,3-triazine 1-oxide and its analogs. Researchers evaluated these compounds for their in vitro and in vivo efficacy. Specifically, compound 2r exhibited a potency four times greater than benznidazole against T. cruzi epimastigotes. Furthermore, the 1,2,3-triazine (1i) and its dihydro analog (3i) reduced parasitemia by 40% in mouse models.
Regarding Leishmaniasis, compound 3r showed activity comparable to miltefosine. Additionally, compound 2i reduced parasitemia by up to 70% in vivo. These results suggest that 1,2,3-triazine derivatives could serve as a foundation for future drug development. The researchers also explored the inhibition of trypanothione reductase as a potential mode of action.
Moreover, these findings highlight the potential of N-oxide derivatives in affecting the antioxidant systems of protozoal parasites. This mechanism of action provides a distinct advantage over existing therapies. Therefore, the researchers believe these analogs warrant further clinical evaluation to address current treatment limitations.
Compound 2r demonstrated exceptional potency, being four times more effective than the standard treatment, benznidazole, in specific models.
Compound 3r showed similar efficacy to miltefosine, while compound 2i significantly reduced parasitemia in animal models, indicating high therapeutic potential.
Disclaimer: This content is for informational and educational purposes only. It is not intended to provide any medical advice or be used for diagnosing or treating any health problem or disease. Patients should always consult with a qualified healthcare professional for medical advice and treatment. Refer to the latest local and national guidelines for clinical practice.
References
1. Navarrete-Carriola DV et al. Discovery of 4-carboxylate-1,2,3-triazine 1-oxide, their 1,2,3-triazine, and the 3,6-dihydro analogs, as new agents against Chagas diseases and Leishmaniasis. Biomed Pharmacother. 2026 May 12. doi: undefined. PMID: 42119274.
2. World Health Organization. Leishmaniasis. Available at: https://www.who.int/news-room/fact-sheets/detail/leishmaniasis
3. Drugs for Neglected Diseases initiative (DNDi). Chagas Disease. Available at: https://dndi.org/diseases/chagas/
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
A study discovers 1,2,3-triazine derivatives that outperform benznidazole and miltefosine in treating Chagas disease and Leishmaniasis in preclinical models...
3 months ago
Explore the emerging role of Brixadi, an extended-release buprenorphine injection, for managing stimulant use disorder through kappa opioid receptor antagonism and steady plasma levels.
Today
A premature neonate developed upper limb compartment syndrome after uterine rupture extruded the arm through a scar defect. Conservative management with continuous monitoring yielded complete functional recovery and normal limb growth at 10-year follow-up, highlighting non-operative safety in selected cases.
Today
Dendritic cells bridge innate and adaptive immunity in myocardial infarction. This review explores their pathological roles, circulating dynamics, novel tolerogenic interventions, and how standard cardiovascular medications modulate dendritic cells to improve post-infarction myocardial repair and patient outcomes.
Today
Endoscopic posterior cervical fusion combines minimally invasive decompression, joint preparation, and rigid screw-rod fixation for atlantoaxial pathologies. Early clinical findings demonstrate solid bony union, excellent symptom relief, and minimal soft-tissue morbidity without significant vascular compromise.
Yesterday
Atherosclerosis involves extensive glycometabolic reprogramming across immune and vascular cells. This review examines how glycolysis, the pentose phosphate pathway, and lactate-driven epigenetic shifts fuel plaque vulnerability, while highlighting novel therapeutic targets like PFKFB3 and LDHA.
Today
